MediPost's Cartistem Receives Approval for Phase 3 Clinical Trial in Japan
[Asia Economy Reporter Ji Yeon-jin] Medipost announced on the 15th that the Japanese Ministry of Health, Labour and Welfare approved the contract for the Phase 3 clinical trial of Catisstem (EVA-001) for patients with knee osteoarthritis on the 13th.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- [Breaking] Blue House expresses "deep regret over Samsung negotiation breakdown... urges both sides to do their best for a final agreement"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
This clinical trial will be conducted on 130 patients with knee osteoarthritis classified as K&L Grade 2 or 3, comparing the efficacy and safety between a single administration group of EVA-001 (Catisstem), an allogeneic umbilical cord blood-derived mesenchymal stem cell product, and a control group receiving hyaluronic acid formulation. The clinical trial will be conducted at eight institutions in Japan.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
